Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.47 |
| ▸ | ACE | P12821 | 4/20 | 0.47 |
| ▸ | MMEL1 | Q495T6 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | USP28 | Q96RU2 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9935035 | 1.00 | MME (0.47) | MMEACEMMEL1ALDH1A1L3MBTL1 | |
| SCHEMBL16198741 | 0.93 | MME (0.44) | MMEACEMMEL1ALDH1A1L3MBTL1 | |
| SCHEMBL20178521 | 0.93 | MME (0.44) | MMEACEMMEL1ALDH1A1L3MBTL1 | |
| SCHEMBL9934166 | 0.91 | MME (0.55) | MMEACEMMEL1ALDH1A1L3MBTL1 | |
| SCHEMBL9934169 | 0.91 | MME (0.55) | MMEACEMMEL1ALDH1A1L3MBTL1 | |
| SCHEMBL9934089 | 0.89 | MME (0.51) | MMEACEMMEL1ALDH1A1L3MBTL1 | |
| SCHEMBL9934094 | 0.89 | MME (0.51) | MMEACEMMEL1ALDH1A1L3MBTL1 | |
| SCHEMBL16198742 | 0.89 | MME (0.46) | MMEACEMMEL1ALDH1A1L3MBTL1 | |
| SCHEMBL9935480 | 0.87 | MME (0.46) | MMEACEMMEL1ALDH1A1L3MBTL1 | |
| SCHEMBL16198744 | 0.87 | MME (0.49) | MMEACEMMEL1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651900-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8563512-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157386-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.